UNLOCKING THE POTENTIAL OF THE
IMMUNE SYSTEM WITH A NEW
CLASS OF THERAPEUTICS

Immunophotonics uses a proprietary glycan polymer with
platform potential to stimulate antigen capture and uptake along
with other immunological processes that are intended to trigger an
immune response, thereby enabling the rejection of cancer and other diseases.
Read More

Unlocking the potential
of the immune system
with a new class of
therapeutics

Proprietary glycan polymer with platform potential
stimulates antigen capture, uptake, and
immunological responses.
Intended to stimulate an immune response, thereby
enabling the rejection of cancer and other
diseases.

Practical Applications to Elevate Modern Medicine

Transforming
Interventional
Oncology

Injecting IP-001 following routine tumor ablations may transform this conventional surgical intervention into a systemically active immunotherapy.

Read More

Elevating
Immunotherapy

IP-001 upregulates T-cell activation, downregulates T-cell exhaustion, and drives stronger Th-1 and cytotoxic T-cell response, which could enhance other immunotherapies, such as checkpoint inhibitors.

Read More

Boosting
Vaccines

IP-001 is a powerful immunoadjuvant that enhances antigen-specific immunity against infectious diseases, including SARS-CoV-2, potentially increasing the efficacy of vaccines.

Read More

Immunophotonics is dedicated to developing its proprietary technology for the benefit of global human health. We believe our multimodal approach can elevate modern medicine, allowing everyday-routine treatments to provide enhanced outcomes.

The Latest News

September 27, 2022

BioPharm America 2022 September 28 & 29

Lu Alleruzzo, Co-Founder & CEO, at Immunophotonics, Inc., will be attending the BioPharm America 2022 conference in Boston on September...
Read More
September 20, 2022

RESI Boston 2022 Partnering Platform

Lu Alleruzzo, Co-Founder & CEO, at Immunophotonics, Inc. will be attending the RESI Boston 2022 Partnering Platform, September 21st &...
Read More
September 20, 2022

SACHS Associates 22nd Annual Biotech in Europe Forum

Dr. Theresa Visarius, Immunophotonics Vice President Business Development and Managing Director of the Swiss subsidiary IPS Biopharma AG will be...
Read More